



Clinical Practice Guideline

Guideline coverage includes NICU KEMH, NICU PCH and NETS WA

Anaemia and Bleeding Disorders

This document should be read in conjunction with the [Disclaimer](#)

Causes of Anaemia

1. Early onset within the first week (Acute or chronic blood loss).
2. Later onset after the first week (Decreased red cell production and/or shortened red cell survival).

In normal healthy newborns haemoglobin levels decrease from a mean of 19.3 g/dl at birth to a nadir of 10.7 g/dl (8.9-12.5) at 9 weeks. The Hb levels of preterm infants are only slightly lower than full term infants however the nadir occurs earlier and is lower.

Early Onset

- Haemolytic disease.
- Fetomaternal.
- Twin to twin transfusion - donor.
- Subgaleal haemorrhage.
- APH - Placenta Praevia, Abruption, Velamentous cord insertion / cord rupture.
- Hepatic rupture.
- Congenital infections i.e. CMV.
- Deceased twin - disseminated intravascular coagulopathy (DIC).
- Isoimmunisation ~ Rhesus disease / ABO incompatibility.

Later Onset

- Iatrogenic blood loss from frequent blood sampling.
- Sepsis, NEC.
- Anaemia of prematurity.
- Haemoglobinopathies.
- Haemorrhagic disease - Vitamin K deficiency, Thrombocytopenia.
- Hereditary spherocytosis.

History

A detailed history is essential. Family and obstetric history may reveal a familial bleeding disorder (haemophilia, rare autosomal recessive platelet function disorders

or thrombocytopaenia-maternal ITP or alloimmune thrombocytopaenia with a previously affected sibling).

Laboratory Tests

Includes:

- Full Blood count and film.
- Group and Direct Coombs (Antiglobulin test).
- Maternal Kleihauer (Determination of fetal haemoglobin in maternal circulation).
- Exclude haemoglobinopathies.
- SBR.
- Coagulation studies. (Normal neonates have a prolonged APTT, especially if preterm, and often the test is not helpful). Factor assays will be more useful for suspected haemophilia.
- Check stools for occult blood if applicable.

While new whole blood platelet factor analysers (PFA) may help diagnose the rare infant with a platelet function defect, in general these disorders and von Willebrand's disease are easier to determine at 6-12 months of age.

Bleeding Disorders

Normal haemostasis requires vascular integrity, normal platelet function and a functioning coagulation system.

Thrombocytopaenia

15% of neonatal patients have a thrombocytopenia of between 100-150,000. Counts below 50,000 should be considered for investigation.

Bleeding may occur with trauma with platelet counts below 50-70,000. Spontaneous bleeding can occur with counts below 20,000. Infants with invasive lines and receiving intensive care procedures may need to be transfused with platelets earlier than well infants.

Bleeding is more likely at any given thrombocytopenic level if the cause is decreased production or there is an associated platelet function defect.

Causes

- Immune - Alloimmune thrombocytopenia (FMAIT), maternal immune thrombocytopenia (ITP).
- Sick infant - sepsis, viral infection, NEC, DIC, hyper-viscosity, RDS.
- Congenital - Kassabach-Merritt Syndrome, Type 2b von Willebrand disease, trisomy 13, 18, 21, autosomal disorders.

Key Points

- Platelet count may quickly drop over the first few days of life.
- Thrombocytopenia may last several weeks.

- Parents need to know if subsequent pregnancies may result in a severely affected fetus requiring monitoring and treatment during their next pregnancy.

Treatment

- Discuss with the haematologist on call who will review the blood film for the size of the platelets (larger platelets are usually younger platelets and indicates increased turnover rather than decreased production).
- Review maternal platelet count, history. Consider FMAIT and type the parents platelets.
- If platelets <20,000-30,000 (well infant) or <50,000 (sick infant) transfuse CMV negative platelets (all platelets are now irradiated and collected with a filter so washing is not required). If FMAIT is likely (well infant and marked thrombocytopenia, request PLA1a negative platelets until the parents platelet typing is known.
- For auto immune thrombocytopenia, IVIG 0.8g/kg, Intragam® 10. See Transfusion Medicine Protocol: [Intragam](#).
- Plasma derived blood components. See [Transfusion Medicine Protocol](#) for infusion protocol and consent requirement.
- Methylprednisolone 2 mg/kg/day may also help stabilise the platelet count. If no improvement bone marrow examination may be required to look for rare congenital causes of thrombocytopenia.
- Head ultrasound.
- Bone marrow analysis may be required.

Vitamin K Deficiency

The **Classical** presentation is at 2-6 days of age in healthy full term infants and occurs because of poor placental transfer of vitamin K, low levels in breast milk and a sterile gut. It can be prevented by a single dose of 0.5 mg for infants < 1500 grams and 1 mg for infants > 1500 grams IM/IV at birth or an oral dose of 2-4 mg at birth with subsequent doses. See Neonatal Medication Protocol: [Phytomenadione \(Vitamin K\)](#).

References




1. American Academy of Pediatrics. Policy statement. Controversies concerning vitamin K and the newborn. <http://aappolicy.aappublications.org/cgi/reprint/pediatrics;112/1/191.pdf>
2. Blank JP, Sheagren TG, Vajaria J, Mangurten HH, Benawra RS, Puppala BL. The role of RBC transfusion in the premature infant. Am J Dis Child. 1984; 138: 831-3.
3. Bussel J. Diagnosis and management of the fetus and neonate with alloimmune thrombocytopenia. J Thromb Haemost 2009; 7 (Suppl. 1): 253--7.
4. Fernández KS, De Alarcón P, Neonatal Thrombocytopenia. Neoreviews 2013; 14-2-e74
5. Hume H, Bard H. Small volume red blood cell transfusions for neonatal patients. Transfusion Medicine Reviews 1995; IX, No 3: 187-199.
6. Kamholz K, Dukhovny D, Kirpalani H, Whyte R, Roberts R, Wang N, et al. Economic evaluation alongside the premature infants in need of transfusion randomised controlled trial. Archives of disease in childhood-fetal and neonatal edition 2012; vol.97(2): available from: <http://fn.bmj.com.ezproxy.library.uwa.edu.au/>
7. Lundstrom U, Siimes MA, Dallman PR. At what age does iron supplementation become necessary in low-birth-weight infants? J Pediatr. 1977; 91: 878-83.
8. Macdonald M.G., Ramasethu J. (April 2002). Atlas of Procedures in Neonatology
9. Moller JC, Schwarz U, Schaible TF, Artlich A, Tegtmeier,FK; Gortner L. Do cardiac output and serum lactate levels indicate blood transfusion requirements in anemia of prematurity? Intensive Care Med. 1996; 22: 472-6.
10. Nunes DOS, Santos AM, Trindade CEP. Red blood cell transfusions in the neonate. Neoreviews. 2011 January 1, 2011;12(1):e13-e19.
11. Ohls RK. Transfusions in the preterm infant. Neoreviews. 2007 September 2007;8(9):e377-e386.
12. Ramasethu J, Luban LC. Red blood cell transfusions in the newborn. Semin Neonatol. 1999; 4: 5-16
13. Von Lindern JS, Lopriore E. Management and prevention of neonatal anemia: current evidence and guidelines. Exp Rev Hematol 2014 April 7 (2) 195-202.
14. Widnes JA. Treatment and prevention of neonatal anemia. Neoreviews. 2008; 9:
15. Widnes JA, Strauss RG. Recombinant erythropoietin in treatment of the premature newborn. Semin Neonatol. 1998; 3: 163-171.
16. Whyte RK, Kirpalani H, Asztalos EV, Andersen C, Blajchman M, Heddle N, et al. Neurodevelopmental outcome of extremely low birth weight infants randomly assigned to restrictive or liberal hemoglobin thresholds for blood transfusion. Pediatrics 2009.

Related WNHS policies, procedures and guidelines

Transfusion Medicine Protocol: [Blood Product Prescription, Consent and Refusal](#)

Transfusion Medicine Protocol: [Intragam](#)

Neonatal Medication Protocol: [Phytomenadione \(Vitamin K\)](#)

| | | | |
|-----------------------|--|-------------------|-------------------------------|
| Document owner: | Neonatal Directorate Management Committee | | |
| Author / Reviewer: | Neonatal Directorate Management Committee | | |
| Date first issued: | June 2006 | | |
| Last reviewed: | 1 st February 2015 | Next review date: | 1 st February 2018 |
| Endorsed by: | Neonatal Directorate Management Committee | Date endorsed: | February 2015 |
| Standards Applicable: | NSQHS Standards: 1  Governance, 6  Clinical Handover, 7  Blood Products | | |

**Printed or personally saved electronic copies of this document are considered uncontrolled.
Access the current version from the WNHS website.**

